Literature DB >> 26910386

Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.

Helena Huerga1, Yolanda Mueller, Gabriella Ferlazzo, Qhubekani Mpala, Paolo Bevilacqua, Béatrice Vasquez, Calorine Noël Mekiedje, Ali Ouattara, Gugu Mchunu, Herman O Weyenga, Francis Varaine, Maryline Bonnet.   

Abstract

INTRODUCTION: The tuberculin skin test (TST) can be used to identify HIV-infected people who would benefit the most from long-term isoniazid preventive therapy (IPT). However, in resource-constrained settings, implementation of the TST can be challenging. The objectives of this study were to assess the feasibility of implementing the TST for IPT initiation and to estimate the proportion of TST-positive incidence among HIV-positive patients in 2 high tuberculosis and HIV burden settings.
METHODS: Two prospective observational cohort studies were conducted under programmatic conditions in Mathare, an urban slum of Nairobi, Kenya, and in rural Shiselweni, Swaziland. HIV-positive adults with negative tuberculosis symptomatic screening underwent the TST. Those testing positive were started on 36-month IPT.
RESULTS: Of 897 and 1021 patients screened in Mathare and Shiselweni, 550 and 696, respectively, were included. Median age was 38 years, 67.7% were female, and 86.8% were on antiretroviral therapy. Among TST-eligible participants, 88.0% (491/558) and 81.8% (694/848) accepted TST and 74.2% (414/558) and 77.1% (654/858) returned for test reading in Mathare and Shiselweni, respectively. The TST was positive in 49.8% (95% confidence interval: 44.9 to 54.6) in Mathare and 33.2% (95% confidence interval: 29.6 to 36.8) in Shiselweni. The 36-month IPT was accepted by 96.1% (198/206) patients in Mathare and 99.5% (216/217) in Shiselweni. IPT implementation at the clinics was managed with no additional staff or extra space.
CONCLUSION: Implementing the TST for IPT initiation was feasible and acceptable in both urban and rural resource-constrained settings. This strategy allows patients who can benefit the most to receive long-term IPT and avoids unnecessarily treating a significant number of patients who do not stand to benefit.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26910386     DOI: 10.1097/QAI.0000000000000895

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  The Risk of Tuberculosis among Populations Living in Slum Settings: a Systematic Review and Meta-analysis.

Authors:  Ekaterina Noykhovich; Sangeeta Mookherji; Amira Roess
Journal:  J Urban Health       Date:  2019-04       Impact factor: 3.671

2.  Relevance and acceptability of using the Quantiferon gold test (QGIT) to screen CD4 blood draws for latent TB infection among PLHIV in South Africa: formative qualitative research findings from the TEKO trial.

Authors:  Deanna Kerrigan; Carrie Tudor; Katlego Motlhaoleng; Limakatso Lebina; Cokiswa Qomfu; Ebrahim Variava; Sandy Chon; Neil Martinson; Jonathan E Golub
Journal:  BMC Health Serv Res       Date:  2018-04-16       Impact factor: 2.655

3.  Health system barriers to implementation of TB preventive strategies in South African primary care facilities.

Authors:  Eva Van Ginderdeuren; Jean Bassett; Colleen Hanrahan; Lillian Mutunga; Annelies Van Rie
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

4.  Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid-Preventive therapies for people living with HIV.

Authors:  Pia Müller; Luís Velez Lapão
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

5.  Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study.

Authors:  Yolanda Mueller; Qhubekani Mpala; Bernhard Kerschberger; Barbara Rusch; Gugu Mchunu; Sikhathele Mazibuko; Maryline Bonnet
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.